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defined as the ratio between ERR for photon /electron, 
photon/DS and photon/IMPT. 
 
 
Results: Regardless of dose-risk model applied, the 
conformal photons were ranked with the highest ERR for all 
cardiac toxicities, whereas IMPT was ranked with the lowest 
(Figure 1a). For cardiac mortality the ERR for photon was 8.1 
(95 % CI: 3.4 to 30.5), while ERR for IMPT were 1.3 (95 % CI: 
1.1 to 2.4). For cardiac disorder and cardiac failure the ERR 
for photon was 5.1 (95 % CI: 0.9 to 15.2) and 2.1 (95 % CI: 0.8 
to 4.6), respectively (Linear model). The corresponding 
results for IMPT were 1.2 (95% CI: 1.0 to 1.7) and 1.1 (95 % 
CI: 1.0 to 1.2). Similar trends were found using the LQ model. 
Relative to IMPT, photons lead to a risk of cardiac mortality 
that was a factor of 6.1 higher (range 5.7 to 7.0), cardiac 
disorder a factor of 4.3 higher (range 4.1 to 4.9) and cardiac 
failure a factor of 2.0 higher (range 1.9 to 2.1) (Figure 1b). 
 
 
 
Conclusion: Across different cardiac morbidity endpoints, 
and despite different dose-risk models used, the results of 
our modelling study were consistently in favour of protons. 
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It has long been hypothesized that the propagation of 
circulating tumour cells (CTCs) is a pre-requisite for the 
development of metastases. However, robust technology to 
reliably isolate CTCs and characterise them at the molecular 
level has only become available in recent years. Thus 
repeated blood sampling for CTCs could provide a non-
invasive method of serially reassessing tumour status and 
evolving tumour biology.  
Patients with stage I-III NSCLC are at high risk of developing 
distant metastases after radiotherapy (RT) or chemo-
radiotherapy treatment. With the advent of new technologies 
to enumerate CTCs, the clinical significance of CTCs before, 
during and after RT has become of great interest. In the 
current era of targeted therapy and the development of 
personalised medicine the question still remains as to 
whether CTCs could be used to identify patients most likely 
to benefit from radical RT and prevent the delivery of futile 
cancer treatments and their associated toxicity. Prospective 
clinical trials have shown the prognostic value of CTC 
enumeration in patients with non-small cell lung cancer 
(NSCLC) and small cell lung cancer (SCLC) (1, 2). Although 
CTCs have been used as a surrogate biomarker in hundreds of 
clinical trials, as yet none have been incorporated into 
standard clinical practice. To date there are few published 
studies evaluating CTC’s in patients undergoing radical 
thoracic RT.  
In my talk I will discuss the following:  
•novel platforms available for isolation of CTCs 
•current data on the evaluation of CTCs as a biomarker in 
NSCLC and SCLC patients treated with RT  
•advantages and limitations of CTCs as a biomarker •future 
directions and the prospect of using CTCs to stratify patients 
in clinical trials 
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Radiotherapy is a mainstay of cancer treatment. Due to it 
high efficacy to inactivate cancer stem cells in the primary 
tumor and regional metastases as well as its increasing ability 
to spare normal tissues, it has a proven curative potential in 
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many cancer types. State-of-the-art radiation treatment 
planning and delivery is fully individualized based on 
anatomical imaging, precise space-resoluted radiation dose 
models, tumor control probability- vs. normal tissue 
complication-models and clinical parameters. These advances 
in personalized radiation oncology can mainly be attributed 
to the revolutionary progress in high-precision radiation 
delivery and planning technology during the past decades and 
have been rapidly translated into clinical practice. In parallel 
radiobiological knowledge has significantly improved during 
the past decades by e.g. unravelling radiobiological 
mechanisms of radioresistance of tumors and volume-dose 
relationships for a host of radiation induced effects in normal 
tissues. This research translated into more efficient radiation 
schedules on a population base and to NTCP parameters 
clinically used for treatment planning in individual patients. 
While several bioassays, including SF2 and plating efficiency 
determined in human tumor biopsies, provided proof-of-
concept of radiobiological mechanisms, these early assays 
could not be applied to tailor a treatment strategy for an 
individual patient. Revolutionary advances in biotechnology 
and tumor biology allow to profile tumors rapidly, thereby 
providing information on resistance parameters (e.g. hypoxia, 
stem cell density, radiosensitivity) which can be rationally 
tested for their prognostic and predictive power for 
radiotherapy. The same applies for biological imaging which 
may be of particular relevance for advancing biology-driven 
individualization of radiation oncology. One uniqueness for 
the development of personalized radiation oncology is that 
already a broad biological stratification of patients can 
substantially enhance individualization as this information 
adds to the fully anatomically-personalized dose-distributions 
achieved today. Therefore biomarker driven high precision 
radiotherapy is in pole position to create a show-case for 
personalized oncology at large.  
This lecture will review preclinical and clinical-translational 
examples of potential strategies to further personalize 
radiation oncology by inclusion of biomarkers. 
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The advent of genomics has revolutionized our understanding 
of breast cancer as several biologically and molecularly 
distinct diseases. New molecular techniques generate data 
about the intrinsic characteristics of a tumour, thereby 
providing useful diagnostic, prognostic and predictive 
information. Commercially available tests have begun to 
fundamentally change the clinicopathological paradigm of 
selecting patients for adjuvant systemic therapies in early 
breast cancer. Several recently published radiosensitivity 
gene expression signatures aim to predict response to 
adjuvant radiotherapy. The ultimate aim of biomarker 
research is to individualise therapies in order to maximise 
tumour response whilst minimizing overtreatment and 
toxicities. This talk will review the strengths and limitations 
of currently available breast cancer-specific molecular tests 
with a view to response prediction. 
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Clinical reports of limited and treatable cancer metastases, a 
disease state that exists in a transitional zone between 
localized and widespread systemic disease, have been 
reported and are now termed oligometastasis. SBRT 
treatment of oligometastases has shown promising local 
control rates (65-97%), and a good toxicity profile (<5% of 
serious adverse events) because the delivered doses are 
ablative and spatially limited. 1, 2 However, most of these 
patients usually recur at distant sites, outside of the 
irradiated area, with a median time to progression of 4 to 6 
months, indicative of occult metastatic deposits at the time 
of treatment. Thus, although SBRT is effective in definitively 
ablating most treated lesions, distant tumors progress 
highlighting the need for better systemic therapies.3  
Immunotherapy has emerged as an independent therapeutic 
modality that can result in objective – even complete – 
responses and significant amelioration of overall survival in 
patients with advanced metastatic tumors. There is an 
emerging opportunity for combining immune therapy 
together with ablative SBRT for oligometastatic patients, 
with the final aim of increasing T cell infiltration into the 
tumor.  
In situ vaccination during lethal RT of few metastases  
Lethal (high) doses of radiation can induce immunogenic 
death in cancer cells, i.e. irradiated cancer cells can trigger 
an antitumor immune response. RT can upregulate the 
necessary “eat-me” signals that promote the uptake of dying 
tumor cells by dendritic cells (DCs) and macrophages4. 
However, a systemic immune response against distant lesions 
(the so-called abscopal effect) is rarely seen. Given the 
beneficial but limited immune modulatory effects of SBRT, 
combination of SBRT with simultaneous activation of other 
immune-pathways could lead to antigen-specific adaptive 
immunity, a phenomenon called “in situ vaccination”.5An 
abscopal effect has been observed when RT was combined 
with immunotherapy and has been proven to be T-cell 
mediated. 6-8 A recent report of patients with melanoma and 
renal cell carcinoma treated with SBRT (20 Gy), in 
combination with IL-2 showed higher than expected abscopal 
responses.9 In a phase I trial combination 8 Gy in 2-3 fractions 
with ipilimumab partial responses were observed in 18% of 
the patients. When dual checkpoint blockade with both anti-
CTLA4 and anti-PD-1 combined with radiation was tested in a 
B16 melanoma model improved responses and abscopal 
effects were observed. Even in the presence of dual 
checkpoint blockade, omission of radiation resulted in high 
rates of relapse.10  
The combination of lethal SBRT to few tumor deposits in 
combination with different immunotherapy strategies triggers 
antitumor immunity. However, the key question that needs 
to be answered is which are the best combinatorial 
strategies, the best timing to combine them and how to 
increase effective homing of antitumor T cells to the 
remaining tumor deposits. Modifying the tumor 
microenvironment in these residual tumors is therefore of 
major importance to improve therapeutic outcome and 
finally cure.  
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